Mark A. Goldsmith - 01 Mar 2025 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Issuer symbol
RVMD
Transactions as of
01 Mar 2025
Net transactions value
$0
Form type
4
Filing time
04 Mar 2025, 19:00:41 UTC
Previous filing
20 Dec 2024
Next filing
19 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Award $0 +97,400 +27% $0.000000 453,302 01 Mar 2025 Direct F1
holding RVMD Common Stock 20,424 01 Mar 2025 Trust F2
holding RVMD Common Stock 20,424 01 Mar 2025 Trust F3
holding RVMD Common Stock 465,604 01 Mar 2025 Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Award $0 +341,100 $0.000000 0 01 Mar 2025 Common Stock 341,100 $40.74 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 264,525 restricted stock units.
F2 Held by Jonathan Goldsmith Revocable Trust.
F3 Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F4 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
F5 One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

President and Chief Executive Officer